Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL434731 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL247259 | 0.78 | ACLY (0.45) | — | |
| Hydrochloric Acid SCHEMBL6043975 | 0.77 | — | — | |
| Hydrochloric Acid SCHEMBL1982707 | 0.77 | — | — | |
| SCHEMBL28096966 | 0.76 | ALOX15 (0.37) | — | |
| SCHEMBL11981935 | 0.76 | KDM4E (0.50) | — | |
| Hydrochloric Acid SCHEMBL15268803 | 0.74 | — | — | |
| SCHEMBL205335 | 0.74 | — | — | |
| SCHEMBL13038657 | 0.74 | KDM4E (0.42) | — | |
| Hydrochloric Acid SCHEMBL15268801 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-3700578-B1 | SYSTEMS FOR RENAL FUNCTION DETERMINATION | MEDIBEACON INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250326732-A1 | CHROMEN-2-ONE MODULATORS OF POLRMT | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-3365339-B1 | NOVEL FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| EP-4447963-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240336568-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | US | disclosed |
| CN-118715015-A | Selective PHD1 inhibitor compounds, compositions and methods of use | 阿克比治疗有限公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2023111990-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20230173111-A1 | COMPOSITIONS AND SYSTEMS FOR RENAL FUNCTION DETERMINATION | MEDIBEACON INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230158175-A1 | METHODS FOR RENAL FUNCTION DETERMINATION | MEDIBEACON INC. | 2023-05-25 | — | — | US | disclosed |
| CN-101213195-B | Substituted glycinamides with antithrombotic and factor XA-inhibiting action | BOEHRINGER INGELHEIM INT | 2012-05-09 | — | — | CN | disclosed |
| US-8044078-B2 | Amino-alkyl amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2011-10-25 | — | — | US | disclosed |
| US-20080280961-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-13 | — | — | US | disclosed |
| EP-1940777-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIGANDS | Sanofi-Aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
| CN-101213195-A | Substituted glycinamides having an antithrombotic and factor xa-inhibiting effect | BOEHRINGER INGELHEIM INT (DE) | 2008-07-02 | — | — | CN | disclosed |
| WO-2007034253-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2007-03-29 | — | — | WO | disclosed |
| CN-1328565-A | Antiviral purine derivatives | UNIV CARDIFF (GB) | 2001-12-26 | — | — | CN | disclosed |
| CN-1318059-A | Isoquinolines as urokinase inhibitors | PFIZER (US) | 2001-10-17 | — | — | CN | disclosed |
| EP-0800516-B1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED (b)-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORP (JP) | 2001-09-19 | — | — | EP | disclosed |
| WO-1996020172-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED β-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | NIPPON STEEL CORPORATION (JP) | 1996-07-04 | — | — | WO | disclosed |